130 related articles for article (PubMed ID: 8343496)
1. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Cadroy Y; Hanson SR; Harker LA
Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Yokoyama T; Kelly AB; Marzec UM; Hanson SR; Kunitada S; Harker LA
Circulation; 1995 Aug; 92(3):485-91. PubMed ID: 7634464
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.
Cadroy Y; Maraganore JM; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1177-81. PubMed ID: 1996320
[TBL] [Abstract][Full Text] [Related]
5. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
6. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
Hanson SR; Griffin JH; Harker LA; Kelly AB; Esmon CT; Gruber A
J Clin Invest; 1993 Oct; 92(4):2003-12. PubMed ID: 8408654
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
10. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
[TBL] [Abstract][Full Text] [Related]
12. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates.
Cadroy Y; Hanson SR; Kelly AB; Marzec UM; Evatt BL; Kunicki TJ; Montgomery RR; Harker LA
Blood; 1994 Jun; 83(11):3218-24. PubMed ID: 8193356
[TBL] [Abstract][Full Text] [Related]
13. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates.
Harker LA; Kelly AB; Hanson SR; Krupski W; Bass A; Osterud B; FitzGerald GA; Goodnight SH; Connor WE
Circulation; 1993 Mar; 87(3):1017-29. PubMed ID: 8443878
[TBL] [Abstract][Full Text] [Related]
14. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.
Tucker EI; Marzec UM; White TC; Hurst S; Rugonyi S; McCarty OJ; Gailani D; Gruber A; Hanson SR
Blood; 2009 Jan; 113(4):936-44. PubMed ID: 18945968
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.
Pujadas-Mestres L; Lopez-Vilchez I; Arellano-Rodrigo E; Reverter JC; Lopez-Farre A; Diaz-Ricart M; Badimon JJ; Escolar G
PLoS One; 2017; 12(2):e0171486. PubMed ID: 28192448
[TBL] [Abstract][Full Text] [Related]
16. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
[TBL] [Abstract][Full Text] [Related]
17. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons.
Schaffer LW; Davidson JT; Vlasuk GP; Dunwiddie CT; Siegl PK
Arterioscler Thromb; 1992 Aug; 12(8):879-85. PubMed ID: 1637785
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thrombus formation in vivo by novel antiplatelet agent.
Marzec UM; Kelly AB; Hanson SR; Lasslo A; Harker LA
Arteriosclerosis; 1990; 10(3):367-71. PubMed ID: 2140503
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin.
Liaw PC; Becker DL; Stafford AR; Fredenburgh JC; Weitz JI
J Biol Chem; 2001 Jun; 276(24):20959-65. PubMed ID: 11294849
[TBL] [Abstract][Full Text] [Related]
20. Effects of red blood cell concentration on hemostasis and thrombus formation in a primate model.
Cadroy Y; Hanson SR
Blood; 1990 Jun; 75(11):2185-93. PubMed ID: 2346782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
